Remove Drugs Remove Genome Project Remove Protein Remove RNA
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52
article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

For example, pilot data from the MHC Diversity in Africa Project has already highlighted the breadth of genetic diversity in Africa – with individual villages having greater genetic diversity than that seen in all of Europe. Understanding individual drug reactions and metabolism Pharmacogenomics is emerging as an important area.

Genome 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 75
article thumbnail

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

Roots Analysis

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. For more details on this emerging domain, check out the following report : SPATIAL GENOMICS MARKET.

Genome 52
article thumbnail

Predictive diagnostics: closing the precision medicine gap

Drug Discovery World

In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. In pursuit of this, the number of new therapeutics in development has boomed.